Impaired acute‐phase humoral immunity is the major factor predicting unfavorable outcomes in multiple myeloma patients with SARS‐CoV‐2 Omicron variants outbreak infection

Ziping Li,Huiwen He,Haolong Li,Fujing Zhang,Xianghong Jin,Shuangjiao Liu,Miao Chen,Yongzhe Li,Junling Zhuang
DOI: https://doi.org/10.1002/ijc.35063
2024-06-26
International Journal of Cancer
Abstract:What's new? Patients with multiple myeloma experienced cancer deterioration and mortality due to COVID‐19, yet profound analyses of Omicron variants‐induced immunity remain limited. This longitudinal study observed severe impaired humoral immunity at 2–4 weeks post‐infection in patients at high risk for hospitalization, while the T‐cell response was relatively intact. Inactivated vaccines continued to show effectiveness against Omicron. The findings suggest that early impaired humoral immunity after infection is a major factor of poor outcomes. A booster at 14–16 weeks post‐infection should be considered for high‐risk multiple myeloma subgroups. At the end of 2022, a huge tide of SARS‐CoV‐2 infection mainly Omicron BA.4/5 developed in China. Multiple myeloma (MM) patients suffered cancer deterioration and mortality from COVID‐19, yet profound analyses of Omicron variants‐induced immunity function are scarce. We presented a longitudinal study in 218 MM patients and 73 healthy controls (HCs), reporting the prognostic factors and dynamic humoral and cellular immune responses. Neutralizing antibody and interferon γ ELISpot assay of SARS‐CoV‐2 was tested at three time points: 2–4, 8–10, and 14–16 weeks after infections. Our data showed older age, active MM, relapsed/refractory MM (R/RMM), immunotherapy, comorbidity, and non‐vaccination were risk factors associated with hospitalization. Severe humoral immunity impairment within 2–4 weeks was especially seen in patients with unvaccinated, older age, immunotherapy, R/RMM and comorbidities, while T‐cell response was relatively intact. Although antibodies of Omicron variants reached positive levels in MM patients at 8–10 weeks, half lost effective antibody protection at 14–16 weeks. However, most seronegative patients (76.2% at 2–4 weeks, 83.3% at 8–10 weeks) could develop effective T‐cell response. Notably, the inactivated wild‐type vaccinated patients exhibited weaker humoral and cellular immunity only at 2–4 weeks, escalating to similar levels as those in HCs later. Our findings indicate impairment of humoral immunity at acute‐phase after infection is the major factor correlated with hospitalization. One‐month suspension of immune therapy is suggested to prevent serious infection. These results confirm the value of inactivated vaccine, but indicate the need for additional booster at 14–16 weeks after infection for high‐risk MM population.
oncology
What problem does this paper attempt to address?